Identification and Clinical Application of Immunological Receptors Targeting Mutated Antigens Expressed by Solid Tumors (Volume II)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 1368
Special Issue Editor
Interests: solid tumor immunotherapy; TCR; CAR; neoantigens; gene and cell therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The Special Issue is a continuation of our previous Special Issue on “Identification and Clinical Application of Immunological Receptors Targeting Mutated Antigens Expressed by Solid Tumors” (https://www.mdpi.com/journal/cancers/special_issues/Immunological_Tumors_Receptors).
Immunotherapy for solid tumors represents the current challenge in cancer treatment. The astonishing results achieved in the treatment of leukemia and lymphomas seem hard to obtain for solid cancers, and the reasons for this are not clear. The key factors in developing successful immunotherapy are the choice of antigen to target tumor cells and the immune receptors used to perform the attack. Many strategies using TCRs specific for shared or mutated cancer antigens and different generations of CARs have been developed, but only a few have shown promising results in patients. There is a need for a deeper understanding of the discriminating factors between successful and unsuccessful therapies.
This Special Issue of Cancers on “Identification and Clinical Application of Immunological Receptors Targeting Mutated Antigens Expressed by Solid Tumors 2.0”, therefore, encompasses new research articles and timely reviews on the identification and clinical application of immunological receptors targeting mutated antigens expressed by solid tumors.
Dr. Anna Pasetto
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- TCR
- CAR
- solid tumors
- mutated antigens
- clinical trials
